Editorial: Nanomedicine targeting central nervous system

In recent years, substantial rise in nervous system disorders have been observed due to lack of early diagnosis and ineffective delivery of drugs to their intended target site. One of the major obstacles to successful treatment is the limited penetration of drugs into the brain, a challenge imposed by the blood-brain barrier (BBB). Although the BBB plays a critical protective role, it also significantly restricts the passage of many drugs and bioactive molecules. To circumvent this, innovative drug-delivery strategies have emerged, transforming the landscape of brain targeting through nanoscale-engineered formulations. Nanomedicines in form of quantum dots, gold nanoparticles, polymeric system, liposomes and polymer-drug conjugates are being extensively investigated for therapeutic applications in high-grade gliomas, neurodegenerative disorders and for diagnostic applications as contrast agents.